SK56496A3 - 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use - Google Patents
5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use Download PDFInfo
- Publication number
- SK56496A3 SK56496A3 SK564-96A SK56496A SK56496A3 SK 56496 A3 SK56496 A3 SK 56496A3 SK 56496 A SK56496 A SK 56496A SK 56496 A3 SK56496 A3 SK 56496A3
- Authority
- SK
- Slovakia
- Prior art keywords
- thienyl
- group
- mmol
- substituted
- vacuo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Polyurethanes Or Polyureas (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK931243A DK124393D0 (da) | 1993-11-03 | 1993-11-03 | Compounds |
PCT/DK1994/000411 WO1995012587A1 (en) | 1993-11-03 | 1994-11-02 | 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SK56496A3 true SK56496A3 (en) | 1996-12-04 |
Family
ID=8102626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK564-96A SK56496A3 (en) | 1993-11-03 | 1994-11-02 | 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0726896A1 (da) |
JP (1) | JPH09504531A (da) |
KR (1) | KR960705797A (da) |
CN (1) | CN1056837C (da) |
AU (1) | AU680062B2 (da) |
CA (1) | CA2175685A1 (da) |
CZ (1) | CZ127296A3 (da) |
DK (1) | DK124393D0 (da) |
FI (1) | FI961872A (da) |
HU (1) | HUT74692A (da) |
NO (1) | NO306159B1 (da) |
NZ (1) | NZ275088A (da) |
PL (1) | PL314182A1 (da) |
RU (1) | RU2138488C1 (da) |
SK (1) | SK56496A3 (da) |
WO (1) | WO1995012587A1 (da) |
ZA (1) | ZA948631B (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2212836C (en) * | 1995-02-13 | 2003-08-12 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
UA52698C2 (uk) * | 1996-10-04 | 2003-01-15 | Х. Луннбек А/С | Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі |
IT1318636B1 (it) * | 2000-07-21 | 2003-08-27 | Roberto Pellicciari | Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato. |
UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
CN1863810B (zh) | 2003-04-09 | 2010-12-01 | 惠氏公司 | [2-(8,9-二氧代-2,6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用 |
TW200514775A (en) | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
EA014233B1 (ru) * | 2006-06-08 | 2010-10-29 | Эли Лилли Энд Компани | Замещенные карбоксамиды |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69102816T2 (de) * | 1990-05-11 | 1995-03-16 | Sankyo Co | Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung. |
DE69325662T2 (de) * | 1992-10-23 | 2000-02-10 | Merck Sharp & Dohme Ltd., Hoddesdon | Dopamin rezeptor subtyp liganden |
-
1993
- 1993-11-03 DK DK931243A patent/DK124393D0/da not_active Application Discontinuation
-
1994
- 1994-11-02 JP JP7512970A patent/JPH09504531A/ja active Pending
- 1994-11-02 WO PCT/DK1994/000411 patent/WO1995012587A1/en not_active Application Discontinuation
- 1994-11-02 SK SK564-96A patent/SK56496A3/sk unknown
- 1994-11-02 NZ NZ275088A patent/NZ275088A/xx unknown
- 1994-11-02 CA CA002175685A patent/CA2175685A1/en not_active Abandoned
- 1994-11-02 EP EP94931523A patent/EP0726896A1/en not_active Withdrawn
- 1994-11-02 HU HU9601167A patent/HUT74692A/hu unknown
- 1994-11-02 CZ CZ961272A patent/CZ127296A3/cs unknown
- 1994-11-02 KR KR1019960702307A patent/KR960705797A/ko not_active Application Discontinuation
- 1994-11-02 PL PL94314182A patent/PL314182A1/xx unknown
- 1994-11-02 RU RU96112168A patent/RU2138488C1/ru active
- 1994-11-02 EP EP99125828A patent/EP0994107A1/en not_active Withdrawn
- 1994-11-02 ZA ZA948631A patent/ZA948631B/xx unknown
- 1994-11-02 AU AU80579/94A patent/AU680062B2/en not_active Ceased
- 1994-11-02 CN CN94194388A patent/CN1056837C/zh not_active Expired - Fee Related
-
1996
- 1996-05-02 NO NO961783A patent/NO306159B1/no not_active IP Right Cessation
- 1996-05-02 FI FI961872A patent/FI961872A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
CN1056837C (zh) | 2000-09-27 |
KR960705797A (ko) | 1996-11-08 |
FI961872A0 (fi) | 1996-05-02 |
ZA948631B (en) | 1995-07-10 |
DK124393D0 (da) | 1993-11-03 |
NO961783D0 (no) | 1996-05-02 |
EP0994107A1 (en) | 2000-04-19 |
RU2138488C1 (ru) | 1999-09-27 |
CA2175685A1 (en) | 1995-05-11 |
JPH09504531A (ja) | 1997-05-06 |
HUT74692A (en) | 1997-01-28 |
PL314182A1 (en) | 1996-09-02 |
AU8057994A (en) | 1995-05-23 |
CZ127296A3 (en) | 1996-09-11 |
HU9601167D0 (en) | 1996-07-29 |
CN1136810A (zh) | 1996-11-27 |
WO1995012587A1 (en) | 1995-05-11 |
NO306159B1 (no) | 1999-09-27 |
NZ275088A (en) | 1997-08-22 |
EP0726896A1 (en) | 1996-08-21 |
AU680062B2 (en) | 1997-07-17 |
FI961872A (fi) | 1996-05-03 |
NO961783L (no) | 1996-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6861858B2 (ja) | Ssao阻害剤 | |
KR100776119B1 (ko) | 트리아졸 유도체 | |
KR101733180B1 (ko) | 신규 1-아릴-3-아자바이사이클로[3.1.0]헥산:제조 방법 및 신경 정신 질환 치료를 위한 용도 | |
WO2002006237A1 (fr) | Medicament comprenant un derive de dicyanopyridine | |
JP5892550B2 (ja) | 縮合イミダゾール誘導体 | |
US6200999B1 (en) | 3-Alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds | |
WO2003070712A1 (en) | Thioibotenic acid and derivatives thereof | |
SK56496A3 (en) | 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use | |
JP6748123B2 (ja) | サクビトリルカルシウム塩 | |
JP6231621B2 (ja) | 新規ベンゾアゼピン誘導体及びその医薬用途 | |
EP2349308A1 (en) | Compounds for treatment of alzheimer's disease | |
CA2725425A1 (en) | Homocysteine synthase inhibitor | |
JP3354258B2 (ja) | 新規なインドール類またはその塩 | |
KR100832750B1 (ko) | N-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물 | |
KR20190126525A (ko) | 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물 | |
JP4172895B2 (ja) | ヘテロジアジノン誘導体 |